Historical wat News Stories
Waters' Q1 Beat Pushes WAT Higher; $4B Debt Looms!
Waters Corporation reported a stronger-than-expected Q1 after closing the BD Biosciences & Diagnostic Solutions deal, driving revenue and EPS beats and a stock jump. Management raised full-year guidance, but roughly $4 billion of acquisition-related debt and near-term refinancing remain material risks to monitor.
Waters (WAT) Down 11% After BD Deal: What's Next!!
Waters shares dropped sharply after closing its acquisition of BD’s diagnostics business, as investors weigh elevated leverage, integration risk and softer short-term guidance against durable demand from PFAS testing, GLP‑1 therapeutics and biologics.
Waters Falls After BD Deal, Q4 Beat, Weak Guide
Waters Corporation reported a solid Q4 2025 but sank after issuing FY2026 guidance that disappointed investors. The close of the $17.5B BD biosciences & diagnostics acquisition amplifies long-term opportunity while raising near-term integration and margin risks investors must monitor.
Waters Stock Slips After BD Integration and Q4 Beat
Waters Corp. reported solid Q4 results and closed its acquisition of BD’s biosciences/diagnostics unit, but integration uncertainty and near-term execution risks weighed on WAT shares. Analysts remain mixed-to-positive as investors watch synergy progress, guidance cadence, and diagnostics revenue ramp.
Waters (WAT) Slumps After BD Spin-Off Integration.
Waters Corp reported a solid Q4 beat but issued conservative 2026 guidance after completing the BD Biosciences & Diagnostics spin-off merger. The deal adds roughly $3B in revenue but pressures margins and raised investor concerns about near-term integration risk, driving recent WAT underperformance.
Waters (WAT) Q4 Beat, BD Deal Sparks Guidance Dip.
Waters reported a Q4 earnings beat driven by recurring revenue, but its 2026 guidance—reflecting the addition of BD’s Biosciences & Diagnostic unit—triggered a sharp stock decline as integration costs and a near-term margin reset weighed on sentiment.
WAT Drops After Guidance; BD Merger Nears Close
Waters Corporation (WAT) cleared shareholder approval for a major BD biosciences acquisition and is set to close the deal imminently. Strong Q4 results were offset by guidance that signaled near-term margin pressure and integration complexity, prompting heightened volatility and a meaningful share-price decline. This article synthesizes the concrete events shaping WAT this week and what investors should watch next.